Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial

Schizophrenia Research

Volumn 80, Issue 1, 2005, Pages 33-43

  Miller, Del D ^a   McEvoy, Joseph P ^b   Davis, Sonia M ^c   Caroff, Stanley N ^d   Saltz, Bruce L ^e   Chakos, Miranda H ^f   Swartz, Marvin S ^b   Keefe, Richard S E ^b   Rosenheck, Robert A ^g   Stroup, T Scott ^h   Lieberman, Jeffrey A ^h  

^a UNIVERSITY OF IOWA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c IQVIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Mental Health Advocates Inc   (United States)

^f SUNY DOWNSTATE MEDICAL CENTER   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic adverse effects; Clinical features; Schizophrenia; Tardive dyskinesia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AKATHISIA; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; PROBABILITY; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; SUBSTANCE ABUSE; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; CHOLINERGIC ANTAGONISTS; COGNITION DISORDERS; DIABETES MELLITUS, TYPE 2; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR AGITATION; RISK-TAKING; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 27744435853     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2005.07.034     Document Type: Article

References (64)

1. A. Abi-Dargham Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort Am. J. Psychiatry 155 6 1998 761 767
2. American Psychiatric Association Diagnostic and Statistical Manual on Mental and Disorders Fourth Edition (DSM-IV) 1994 American Psychiatric Press, Inc. Washington, D.C.
3. T.R. Barnes A rating scale for drug-induced akathisia Br. J. Psychiatry 154 1989 672 676
4. J. Cami, and M. Farre Drug addiction N. Engl. J. Med. 349 10 2003 975 986
5. M.H. Chakos Incidence and correlates of tardive dyskinesia in first episode of schizophrenia Arch. Gen. Psychiatry 53 4 1996 313 319
6. A.V. Chobanian Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure JAMA 289 19 2003 2560 2572
7. C.U. Correll Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies Am. J. Psychiatry 161 3 2004 414 425
8. G.E. Crane Prevention and management of tardive dyskinesia Am. J. Psychiatry 129 4 1972 466 467
9. T.J. Crow Does tardive dyskinesia exist? Mod. Probl. Pharmacopsychiatry 21 1983 206 219
10. J.G. Csernansky Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients Psychopharmacology (Berlin) 81 1983 115 118
11. E.J. Davis Tardive dyskinesia and type II schizophrenia Br. J. Psychiatry 160 1992 253 256
12. L. Dixon Increased tardive dyskinesia in alcohol-abusing schizophrenic patients Compr. Psychiatry 33 2 1992 121 122
13. R.E. Drake Diagnosis of alcohol use disorders in schizophrenia Schizophr. Bull. 16 1 1990 57 67
14. R. Druckman Chronic involuntary movements induced by phenothiazines J. of Nerv. Ment. Dis. 135 1962 69 76
15. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the expert committee on the diagnosis and classification of diabetes mellitus Diabetes Care, Suppl. 1 2003 S5 S20
16. M.B. First Structural Clinical Interview for DSM-IV (SCID-I): User's Guide and Interview- Research Version 1995 Biometric Research Department, New York Psychiatric Institute New York, NY
17. L. Ganzini The prevalence of tardive dyskinesia in neuroleptic treated diabetics Arch. Gen. Psychiatry 48 1991 259 263
18. G. Gardos, and J.O. Cole Tardive dyskinesia and anticholinergic drugs Am. J. Psychiatry 140 2 1983 200 202
19. W.M. Glazer Tardive dyskinesia. A discontinuation study Arch. Gen. Psychiatry 41 6 1984 623 627
20. R.Z. Goldstein, and N.D. Volkow Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex Am. J. Psychiatry 159 10 2002 1642 1652
21. W. Greil Tiapride: effects on tardive dyskinesia and on prolactin plasma concentrations Neuropsychobiology 14 1985 17 22
22. Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology-Revised. in: Dept of Health, Education, and Welfare Publication No. ADM 534-537. Public Health Service; Alcohol, Drug Abuse, and Mental Health Administration: NIMH. Rockville, MD, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs.
23. W. Guy The prevalence of abnormal involuntary movements among chronic schizophrenics Int. Clin. Psychopharmacol. 1 2 1986 134 144
24. Y. Hochberg A sharper Bonferroni procedure for multiple tests of significance Biometrika 75 1988 800 803
25. A.C. Iager Defect symptoms and abnormal involuntary movement in schizophrenia Biol. Psychiatry 21 8-9 1986 751 755
26. D.V. Jeste, and R.J. Wyatt Changing epidemiology of tardive dyskinesia: an overview Am. J. Psychiatry 138 1981 297 309
27. D.V. Jeste Association of abnormal involuntary movements and negative symptoms Psychopharmacol. Bull. 20 3 1984 380 381
28. D.V. Jeste Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients Arch. Gen. Psychiatry 52 9 1995 756 765
29. D.V. Jeste Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients Am. J. Psychiatry 156 2 1999 309 311
30. J.M. Kane, and J.M. Smith Tardive dyskinesia: prevalence and risk factors, 1959-1979 Arch. Gen. Psychiatry 39 1982 473 481
31. J.M. Kane Integrating incidence and prevalence of tardive dyskinesia Psychopharmacol. Bull. 22 1 1986 254 258
32. S.R. Kay The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr. Bull. 13 2 1987 261 276
33. R.S.. Keefe Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale Schizophr. Bull. 29 1 2003 45 55
34. B.J. Kinon Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods Prog. Neuro-Psychopharmacol. Biol. Psychiatry 28 6 2004 985 996
35. M. Laruelle Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects Proc. Natl. Acad. Sci. U. S. A. 93 17 1996 9235 9240
36. J.A. Lieberman Prediction of relapse in schizophrenia Arch. Gen. Psychiatry 44 7 1987 597 603
37. J.P. Lindenmayer Positive and negative subtypes in acute schizophrenia Compr. Psychiatry 25 4 1984 455 464
38. J.V. Lucey, and T.G. Dinan Orofacial dyskinesia and the alcohol dependence syndrome Psychol. Med. 22 1 1992 79 83
39. T.C. Manschreck Abnormal involuntary movements and chronic schizophrenic disorders Biol. Psychiatry 27 2 1990 150 158
40. H. Morgenstern, and W.M. Glazer Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale tardive dyskinesia study Arch. Gen. Psychiatry 50 9 1993 723 733
41. S. Mukherjee Possible association between tardive dyskinesia and altered carbohydrate metabolism [letter] Arch. Gen. Psychiatry 42 1985 205
42. A.A. Olivera Tardive dyskinesia in psychiatric patients with substance use disorders Am. J. Drug Alcohol Abuse 16 1-2 1990 57 66
43. L.A. Opler Positive and negative syndromes in chronic schizophrenic inpatients J. of Nerv. Ment. Dis. 172 6 1984 317 325
44. D.G. Owens Involuntary disorders of movement in chronic schizophrenia - the role of the illness and its treatment Psychopharmacology, Suppl. 2 1985 79 87
45. J.S. Paulsen Neuropsychological impairment in tardive dyskinesia Neuropsychology 8 2 1994 227 241
46. J.S. Paulsen Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: a prospective longitudinal study Psychopharmacology (Berl) 123 4 1996 307 314
47. M.A. Richardson Tardive dyskinesia and depressive symptoms in schizophrenics Psychopharmacol. Bull. 21 1 1985 130 135
48. B.L. Saltz Prospective study of tardive dyskinesia incidence in the elderly Jama 266 17 1991 2402 2406
49. B.L. Saltz Aging and tardive dyskinesia R. Yassa N.P.V. Nair D.V. Jeste Neuroleptic-Induced Movement Disorders 1997
50. N.R. Schooler, and J.M. Kane Research diagnoses for tardive dyskinesia Arch. Gen. Psychiatry 39 4 1982 486 487
51. J. Sigwald Neurological complications of neuroleptic medication Rev. Neurol. (Paris) 100 1959 553 595
52. T.S. Stroup The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development Schizophr. Bull. 29 1 2003 15 31
53. M.S. Swartz Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial Schizophr. Bull. 29 1 2003 33 43
54. Swartz, M., et al., in press. Substance use in persons with schizophrenia: Baseline prevalence and correlates from the NIMH CATIE study. J. of Nerv. Ment. Dis.
55. K. Tracy Interrater reliability issues in multicenter trials, Part I: theoretical concepts and operational procedures used in Department of Veterans Affairs Cooperative Study #394 Psychopharmacol. Bull. 33 1 1997 53 57
56. D. Umbricht, and J.M. Kane Medical complications of new antipsychotic drugs Schizophr. Bull. 22 3 1996 475 483
57. J.L. Waddington Tardive dyskinesia in schizophrenia and other disorders: associations with ageing, cognitive dysfunction and structural brain pathology in relation to neuroleptic exposure Hum. Psychopharmacol. 2 1987 11 22
58. J.L. Waddington, and A.G. Molloy Duration of treatment relationships for involuntary movements (tardive dyskinesia): concordance between cross-sectional, clinical, and longitudinal animal studies? Arch. Gen. Psychiatry 43 2 1986 191 192
59. J.L. Waddington, and H.A. Youssef Late onset involuntary movements in chronic schizophrenia: relationship of 'tardive' dyskinesia to intellectual impairment and negative symptoms Br. J. Psychiatry 149 1986 616 620
60. J.L. Waddington, and H.A. Youssef An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms Am. J. Psychiatry 143 1986 1162 1165
61. M.G. Woerner Diabetes and development of tardive dyskinesia Am. J. Psychiatry 150 6 1993 966 968
62. M.G. Woerner Prospective study of tardive dyskinesia in the elderly: rates and risk factors Am. J. Psychiatry 155 11 1998 1521 1528
63. R. Yassa, and D.V. Jeste Gender differences in tardive dyskinesia: a critical review of the literature Schizophr. Bull. 18 1992 701 715
64. R. Yassa Tardive dyskinesia in elderly psychiatric patients: a 5-year study Am. J. Psychiatry 149 9 1992 1206 1211